Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KamRAB- HRIG · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 20 IU/kg KamRAB + Active Anti-Rabies Vaccine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| KamRAB - HRIG | DRUG | wound infiltration or IM injection |
Inclusion Criteria: * Healthy children (male and female) ages 0 months to \<17 years. * Have been exposed or possibly exposed to rabies. * Are indicated to receive post-exposure prophylaxis (PEP) against rabies infection. * Have documented informed consent from the child's parent(s) or legal guardi...
KamRAB- HRIG is used for rabies post-exposure prophylaxis in children exposed to rabies. It is given as a single dose together with an active rabies vaccine. Kamada Ltd. developed it as a human rabies immune globulin product for passive immunization after suspected rabies exposure.
KamRAB- HRIG is developed by Kamada Ltd., an Israeli biopharmaceutical company whose shares trade under the ticker KMDA. Kamada is the sponsor of the clinical study of KamRAB- HRIG in children exposed to rabies conducted in the United States.
KamRAB- HRIG is in Phase 3 development. Its single registered trial, NCT02912845, is listed as a Phase 3 post-marketing study and has completed. The study enrolled 30 children exposed to rabies in the United States and was an uncontrolled, non-randomized, open-label design.
KamRAB- HRIG has been studied in one registered clinical trial, NCT02912845, titled a post-marketing study of KamRAB administered as a single dose with active rabies vaccine in children exposed to rabies. The trial was Phase 3, completed, enrolled 30 participants, and was conducted in the United States.
Yes, KamRAB- HRIG and KamRAB - HRIG refer to the same product from Kamada Ltd. The only difference is spacing and punctuation in the name. Both spellings point to the same human rabies immune globulin candidate studied in children exposed to rabies under trial NCT02912845.